Journal List > Perinatology > v.30(4) > 1144136

Perinatology. 2019 Dec;30(4):249-253. Korean.
Published online Dec 31, 2019.
Copyright © 2019 The Korean Society of Perinatology
Serious Necrotizing Enterocolitis in a Neonate Treated with Octreotide for Congenital Chylothorax
Min Jeong Jo, MD, Do-Hyun Kim, MD, PhD, and Hee Sup Kim, MD, PhD
Department of Pediatrics, Dongguk University Ilsan Hospital, Dongguk University College of Medicine, Goyang, Korea.

Correspondence to Do-Hyun Kim, MD, PhD. Department of Pediatrics, Dongguk University Ilsan Hospital, 27 Dongguk-ro, Ilsandong-gu, Goyang 10326, Korea. Tel: +82-31-961-7184, Fax: +82-31-961-7182, Email:
Received Sep 20, 2019; Revised Oct 21, 2019; Accepted Oct 26, 2019.

This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License ( which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.


The somatostatin analog octreotide has recently been introduced in the treatment of infants with chylothorax. The safety profile of octreotide has not been fully evaluated. Octreotide reduces the splanchnic blood flow in a dose-dependent manner, affecting the entire gastrointestinal tract. Some concern has been recently raised regarding the potential implications of this effect in the development of necrotizing enterocolitis in neonates receiving octreotide for congenital hyperinsulinism or chylothorax. To our knowledge, there is no case report linking the use of octreotide with necrotizing enterocolitis in Korea. We report a case of serious necrotizing enterocolitis in a neonate treated with octreotide for congenital idiopathic chylothorax.

Keywords: Octreotide; Enterocolitis, necrotizing; Chylothorax; Newborn


Fig. 1
The initial infantogram showed massive right pleural effusion.
Click for larger imageDownload as PowerPoint slide

Fig. 2
Infantogram (A) and abdominal ultrasonography (B) showed the findings consistent with necrotizing enterocolitis. Notable features include generalized bowel loop distension, pneumatosis coli (A, arrow), and portal venous air (B, arrows).
Click for larger imageDownload as PowerPoint slide

Fig. 3
Intraoperative findings were consistent with necrotizing enterocolitis involving extensive areas of jejunum, ileum, and colon.
Click for larger imageDownload as PowerPoint slide


Table 2
Summary of Cases of Octreotide Associated Necrotizing Enterocolitis
Click for larger imageClick for full tableDownload as Excel file

1. Valentine VG, Raffin TA. The management of chylothorax. Chest 1992;102:586–591.
2. Ulíbarri JI, Sanz Y, Fuentes C, Mancha A, Aramendia M, Sánchez S. Reduction of lymphorrhagia from ruptured thoracic duct by somatostatin. Lancet 1990;336:258.
3. Au M, Weber TR, Fleming RE. Successful use of somatostatin in a case of neonatal chylothorax. J Pediatr Surg 2003;38:1106–1107.
4. Yin R, Zhang R, Wang J, Yuan L, Hu L, Jiang S, et al. Effects of somatostatin/ octreotide treatment in neonates with congenital chylothorax. Medicine (Baltimore) 2017;96:e7594
5. Rasiah SV, Oei J, Lui K. Octreotide in the treatment of congenital chylothorax. J paediatr Child Health 2004;40:585–588.
6. Lam JC, Aters S, Tobias JD. Initial experience with octreotide in the pediatric population. Am J ther 2001;8:409–415.
7. Austin JD, Hofman P, Anderson BJ. Life-threatening hyperkalemia following partial pancreatectomy for neonatal hyperinsulinism. Pediatr Crit Care Med 2008;9:e17–e19.
8. Reck-Burneo CA, Parekh A, Velcek FT. Is octreotide a risk factor in necrotizing enterocolitis? J pediatr Surg 2008;43:1209–1210.
9. Laje P, Halaby L, Adzick NS, Stanley CA. Necrotizing enterocolitis in neonates receiving octreotide for the management of congenital hyperinsulinism. Pediatr Diabetes 2010;11:142–147.
10. Hawkes CP, Adzick NS, Palladino AA, De León DD. Late presentation of fulminant necrotizing enterocolitis in a child with hyperinsulinism on octreotide therapy. Horm Res Paediatr 2016;86:131–136.
11. Mohseni-Bod H, Macrae D, Slavik Z. Somatostatin analog (octreotide) in management of neonatal postoperative chylothorax: is it safe? Pediatr Crit Care Med 2004;5:356–357.
12. Sivasli E, Dogru D, Aslan AT, Yurdakok M, Tekinalp G. Spontaneous neonatal chylothorax treated with octreotide in Turkey: a case report. J Perinatol 2004;24:261–262.
13. Paget-Brown A, Kattwinkel J, Rodgers BM, Michalsky MP. The use of octreotide to treat congenital chylothorax. J Pediatr Surg 2006;41:845–847.
14. Demirbilek H, Shah P, Arya VB, Hinchey L, Flanagan SE, Ellard S, et al. Long-term follow-up of children With congenital hyperinsulinism on octreotide therapy. J Clin Endocrinol Metab 2014;99:3660–3667.
15. Henry MC, Moss RL. Neonatal necrotizing enterocolitis. Semin Pediatr Surg 2008;17:98–109.
16. Martinez-Tallo E, Claure N, Bancalari E. Necrotizing enterocolitis in full-term or near-term infants: risk factors. Biol Neonate 1997;71:292–298.
17. Abbo O, Harper L, Michel JL, Ramful D, Breden A, Sauvat F. Necrotizing enterocolitis in full term neonates: is there always an underlying cause? J Neonatal Surg 2013;2:29.
18. Ostlie DJ, Spilde TL, St Peter SD, Sexton N, Miller KA, Sharp RJ, et al. Necrotizing enterocolitis in full-term infants. J Pediatr Surg 2003;38:1039–1042.
19. Martini S, Aceti A, Lima M, Maffi M, Faldella G, Corvaglia L. Octreotide in a critically ill extremely preterm infant with perforated necrotizing enterocolitis. Pediatrics 2016;138:e20160467